Supplement researchSourced from PubMed and NIH
NutriStack
Free iPhone appUpdated September 28, 2026

Supplement × Prescription·Evidence index

5-HTP and Levodopa/Carbidopa: what the research found

PubMed indexes 8 records that name 5-HTP and Levodopa/Carbidopa together, either in the title or in an interaction, co-administration, or pharmacokinetic context. The key findings come first, in the authors’ own words, followed by every study with its design and PubMed link.

A summary of published research, not medical advice. A pharmacist can check any combination against your full list of medicines and supplements.

Key findings

What the studies concluded.

Reviews and human studies first. Each quote is the authors’ own conclusion about their study, not a NutriStack assessment, and a single study is not a consensus.

“This study provides preliminary evidence of clinical benefit of 5-HTP against LIDs in PD. Larger studies with a longer treatment duration and a wider range of doses are warranted to corroborate these findings.”

Meloni et al. · 2020 · Human study · details

“In the other four patients the TPH gene analysis was normal. In conclusion, this new neurodevelopmental syndrome responsive to treatment with 5-hydroxytryptophan and carbidopa might result from an overall reduced capacity of serotonin production due to a TPH gene regulatory defect, unknown factors inactivating the TPH enzyme, or selective loss of serotonergic neurons.”

Ramaekers et al. · 2001 · Human study · details

“Plasma kynurenine was also determined to be high in seven of 15 patients wth idiopathic scleroderma, but not in eight patients with intention myoclonus treated with L-5HTP and a decarboxylase inhibitor and in whom scleroderma did not develop or in 10 patients with Parkinson's disease treated wth L-dopa and carbidopa.”

The research

8 studies naming 5-HTP and Levodopa/Carbidopa.

Strongest relevance first: papers naming both substances in the title, then human trials and systematic reviews.

Efficacy and safety of 5-Hydroxytryptophan on levodopa-induced motor complications in Parkinson's disease: A preliminary finding.

Journal of the neurological sciences · 2020 · PMID 32464351

Randomized Controlled Trial

“This study provides preliminary evidence of clinical benefit of 5-HTP against LIDs in PD. Larger studies with a longer treatment duration and a wider range of doses are warranted to corroborate these findings.”

Meloni et al. · Authors' conclusion

Names both 5-HTP and Levodopa/Carbidopa in its title.

A novel neurodevelopmental syndrome responsive to 5-hydroxytryptophan and carbidopa.

Molecular genetics and metabolism · 2001 · PMID 11386854

Clinical TrialControlled Clinical Trial

“In the other four patients the TPH gene analysis was normal. In conclusion, this new neurodevelopmental syndrome responsive to treatment with 5-hydroxytryptophan and carbidopa might result from an overall reduced capacity of serotonin production due to a TPH gene regulatory defect, unknown factors inactivating the TPH enzyme, or selective loss of serotonergic neurons.”

Ramaekers et al. · From the abstract

Names both 5-HTP and Levodopa/Carbidopa in its title.

5-Hydroxytryptophan and carbidopa in spontaneously hypertensive rats.

Journal of hypertension · 1989 · PMID 2786023

Comparative StudyAnimal study

“Spontaneously hypertensive rats treated with 5-HTP plus carbidopa had significantly lower blood pressure levels, lower pulse rates, reductions in food and water intake, salt and water excretion, and a loss of body weight, when compared with the control SHR. These data indicate that enhanced brain formation of 5-HT can give rise to metabolic and circulatory responses with a resultant lowering of blood pressure.”

Itskovitz et al. · From the abstract

Names both 5-HTP and Levodopa/Carbidopa in its title.

Development of a scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa.

The New England journal of medicine · 1980 · PMID 6997735

Case ReportsClinical Trial15 participants

“Plasma kynurenine was also determined to be high in seven of 15 patients wth idiopathic scleroderma, but not in eight patients with intention myoclonus treated with L-5HTP and a decarboxylase inhibitor and in whom scleroderma did not develop or in 10 patients with Parkinson's disease treated wth L-dopa and carbidopa.”

Sternberg et al. · From the abstract

Names both 5-HTP and Levodopa/Carbidopa in its title.

Anorectic interaction and safety of 5-hydroxytryptophan/carbidopa plus phentermine or diethylpropion in rat.

Behavioural pharmacology · 2021 · PMID 33660661

Animal study

“Both combinations induced around 20% body weight loss after 3 months of oral administration. Results suggest that 5-HTP/30 mg/kg carbidopa potentiates the anorectic effect of diethylpropion and phentermine with an acceptable safety profile, but further clinical studies are necessary to establish their therapeutic potential in the obesity treatment.”

Limón-Bernal et al. · From the abstract

Names both 5-HTP and Levodopa/Carbidopa in its title.

Limitations

What this evidence cannot tell you.

Search-based evidence indexes have real limits, and it is worth being explicit about them:

How to read this page

A literature summary, not guidance.

NutriStack

Track what you actually take.

NutriStack is a free iPhone app for organising a supplement routine: what you take, when, and what the published record says about it. Its exploratory interaction checker covers 5-HTP, Levodopa/Carbidopa, and several hundred other substances.

Log your routine, get reminders at the times you choose, and scan a label to add a product. The checker is a research and organisation tool, not a clinical decision aid.

NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.